PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE

Inclusion Criteria: * hospitalised for STEMI or non-STEMI, as defined by the 4th universal definition of MI * underwent coronary angiography during the index hospitalisation showing at least one epicardial coronary artery with ≥50% stenosis and a 2nd epicardial coronary artery with ≥20% stenosis on the coronary angiogram * Body Mass Index (BMI) ≥18 to ≤40 kg/m2 * White Blood Cell count ≥ 7.0 X 103/uL during admission Exclusion Criteria: * Prior coronary artery bypass grafting (CABG) * CABG planned within 12 months of admission * Known history of drug or alcohol abuse within 5 years of screening * History of QT prolongation associated with other medications that required discontinuation of that medication * Congenital long QT syndrome * Systolic blood pressure persistently \<90 mm Hg or HR\<40 beats per minute at time of enrolment * ALT \>2 x ULN, cirrhosis, recent hepatitis, or positive screening test for hepatitis B (hepatitis B surface antigen) or other viral hepatitis * Uncontrolled Type 1 or Type 2 DM defined as HbA1c \>10% or 74.9 mmol/mol (by IFCC) * Any planned coronary revascularisation, valve surgery, or cardiac resynchronisation within 7 months after randomisation * Any concomitant medications known to be associated with Torsades de Pointes or potent inducers of cytochrome P450 3A4 (CYP3A4) * Planned treatment with zileuton, leukotriene receptor antagonists (e.g., montelukast) during trial * Participated in another interventional clinical study with an investigational pharmaceutical product during the last 3 months * Known hypersensitivity to drugs with a similar chemical structure or class of study drugs or any of the excipients of the product * Known conditions that either increase the risk of performing the CT or make the procedure technically impractical * No severe asthma attack that require emergency treatment or hospitalisation in the past 6 months * Had severe course of COVID-19 (extracorporeal membrane oxygenation, mechanically ventilated), and/or had a confirmed case of COVID-19 within 4 weeks of Screening Visit